Form 4: United Therapeutics' President and COO, Michael Benkowitz, Executes Stock Options and Sells Shares Under 10b5-1 Plan

Sentiment:

SEC Form 4 Filing


Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

  • On March 10, 2025, Michael Benkowitz, President and COO of United Therapeutics, exercised stock options to acquire 2,000 shares of common stock at a price of $111 per share.
  • Following the exercise, Mr. Benkowitz sold a total of 1,697 shares of common stock at prices ranging from $313.93 to $323.99 per share.
  • These transactions were executed under a Rule 10b5-1 trading plan established on August 7, 2024.
  • The shares are held in a trust where Mr. Benkowitz's family members are beneficiaries, and he has sole investment and voting power.
  • After these transactions, Mr. Benkowitz indirectly owns 0 shares through the trust and directly owns 2,648 shares, which includes 71 shares acquired through the Employee Stock Purchase Plan on March 4, 2025.

Sentiment

Score: 5

Explanation: Neutral sentiment as it reflects routine insider trading activity under a pre-arranged plan.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It indicates that a company executive is exercising stock options and selling shares, which is a common practice. The use of a 10b5-1 plan suggests the transactions were pre-planned to avoid accusations of insider trading.

Key Dates

DateDescription
03/15/2021Date stock options were exercisable
08/07/2024Date of Rule 10b5-1 trading plan adoption
03/04/2025Date of acquisition of 71 shares under the Employee Stock Purchase Plan
03/10/2025Date of stock option exercise and share sales
03/11/2025Date of signature
03/15/2028Expiration date of stock options

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.